SHA:600703.SS 2 February 2026

March 18, 2026, 8:06 AM EDT. Tandem Diabetes Care (TNDM) shares jumped 9.1% to $23.91 on strong volume following Piper Sandler's upgrade to "Overweight" and price target hike to $33. The move reflected optimism about pharmacy pricing benefits and international market opportunities after the company's Q4 2025 earnings call. However, consensus earnings per share (EPS) estimates for the quarter fell 4% over the past month, signaling caution. TNDM expects a quarterly loss of $0.46 per share, 31.3% wider year-over-year, with revenue projected up 2.8% to $240.95 million. The stock holds a Zacks Rank #3 (Hold), highlighting mixed signals as positive price action contrasts with downgrading earnings forecasts. Investors should monitor if recent gains translate into sustained strength amid evolving estimates.